摘要
目的观察对比阿托伐他汀与瑞舒伐他汀治疗冠心病的临床疗效。方法选择2011年5月～2012年5月期间我院收治的冠心病患者108例，根据随机性原则将其平均分为研究组与对照组。两组患者均给予基础药物治疗，在此基础上研究组采用瑞舒伐他汀治疗，对照组采用阿托伐他汀治疗。结果治疗1年后，研究组血浆TG、TC、LDL—C指标明显低于对照组（P〈0．05），HDL—C指标明显高于对照组（P〈0．05）。结论阿托伐他汀与瑞舒伐他汀治疗冠心病，后者的作用更强、疗效更显著、安全可靠，适于临床广泛应用。
Objective To observe the clinical efficacy of atorvastatin versus rosuvastatin in the treatment of coronary heart disease. Methods A total of 108 patients with coronary heart disease admitted to our hospital from May 2011 to May 2012 were randomly and equally divided into study group and control group. In addition to basic medication, the study group and control group received rosuvastatin and atorvastatin, respectively. Results After one year of treatment, the study group had significantly lower plasma levels of triglyeerides, total cholesterol, and low-density lipoprotein cholesterol （P〈0.05） and a significantly higher plasma high-density lipoprotein cholesterol level （P〈0.05）, as compared with the control group. Conclusion Rosuvastatin has better efficacy than atorvastatin in the treatment of coronary heart disease and is safe and reliable, so it holds promise for wide clinical application.
出处
《心血管病防治知识（学术版）》
2014年第3期36-37,共2页
Prevention and Treatment of Cardiovascular Disease
关键词
阿托伐他汀
瑞舒伐他汀
冠心病
Atorvastatin
Rosuvastatin
Coronary heart disease
